EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Validity of gold‐standard clinical outcome assessments in U.S. Latinx‐Hispanic participants enrolled in Alzheimer's disease clinical trials: A literature review

Lorena H Monserratt, Jessica A Morales, Aisha Mohammed, Stephanie Ovalle-Eliseo, Gabriela Islas-Huerta, Lauren A Perez, Mirella Díaz-Santos iD

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70918 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Lorena H Monserratt und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Katherine and Benjamin Kagan Alzheimer's Disease Treatment Development Program, University of California, Los Angeles, Los Angeles, California, U…. Hauptthemen laut MEDLINE: Alzheimer Disease, Clinical Trials as Topic, Hispanic or Latino, Neuropsychological Tests. Die Arbeit nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is an urgency to achieve equitable representation of Latinx‐Hispanic participants in Alzheimer's disease (AD) clinical trials. Valid instruments for these communities contribute to the generalizability of clinical trial outcomes. The aim of this study was to review articles reporting studies that conducted a thorough assessment of the validity and reliability of three gold‐standard cognitive measures with U.S. Latinx‐Hispanic communities. We reviewed validity/reliability studies of the Clinical Dementia Rating (CDR), Alzheimer's Disease Assessment Scale—Cognition (ADAS‐Cog), and Repeatable Battery of the Assessment of Neuropsychological Scales (RBANS) among U.S. Latinx‐Hispanic communities. Database searches included PubMed and PsycINFO. For the CDR, one study assessed validity and the other reliability. For the RBANS, one study evaluated the diagnostic accuracy, and another conducted an equating analysis. No studies addressed the validation/reliability of ADAS‐Cog. Our literature review revealed limited studies examining the validity and reliability of the CDR, ADAS‐Cog, and RBANS in U.S. Latinx‐Hispanic communities. Highlights Various government entities are mandating increased enrollment of the Latinx‐Hispanic communities in AD clinical trials without considering the potential negative impact of study results when invalid COAs are used in underrepresented communities. Our investigation demonstrates three gold‐standard COAs routinely used in AD clinical trials have mostly not been validated on the Latinx‐Hispanic communities residing in the United States. We recommend specific actions to support the development of valid clinical outcome measures for the Latinx‐Hispanic communities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseClinical Trials as TopicHispanic or LatinoNeuropsychological TestsOutcome Assessment, Health CareHumansReproducibility of ResultsUnited States

Stichwörter der Autor:innen

ADAS‐CogAlzheimer's diseaseCDRLatinx‐HispanicRBANSUnited Statesclinical trialsvalidity

Autor:innen und Institutionen

  • The Katherine and Benjamin Kagan Alzheimer's Disease Treatment Development Program, University of California, Los Angeles, Los Angeles, California, USA.
  • Mary S. Easton Center for Alzheimer's Research and Care at UCLA, Los Angeles, California, USA.
  • Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Equity for Latinx-Hispanic Healthy Aging (ELHA) Lab, University of California, Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Mirella Díaz-Santos

Förderung

  • the National Institute on Aging

Zitieren

APA

Monserratt, L. H., Morales, J. A., Mohammed, A., Ovalle-Eliseo, S., Islas-Huerta, G., Perez, L. A., & Díaz-Santos, M. (2025). Validity of gold‐standard clinical outcome assessments in U.S. Latinx‐Hispanic participants enrolled in Alzheimer's disease clinical trials: A literature review. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70918

Vancouver

Monserratt LH, Morales JA, Mohammed A, Ovalle-Eliseo S, Islas-Huerta G, Perez LA, et al. Validity of gold‐standard clinical outcome assessments in U.S. Latinx‐Hispanic participants enrolled in Alzheimer's disease clinical trials: A literature review. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70918

BibTeX
@article{Monserratt2025,
  author = {Monserratt, Lorena H and Morales, Jessica A and Mohammed, Aisha and Ovalle-Eliseo, Stephanie and Islas-Huerta, Gabriela and Perez, Lauren A and Díaz-Santos, Mirella},
  title = {Validity of gold‐standard clinical outcome assessments in U.S. Latinx‐Hispanic participants enrolled in Alzheimer's disease clinical trials: A literature review},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70918}
}
Kostenlos starten →